Aceto closes transaction for acquisition of Rising's assets

NewsGuard 100/100 Score

Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced that it has closed the previously announced transaction for its wholly-owned subsidiary to acquire certain assets of Rising Pharmaceuticals, Inc ("Rising").

The Company will hold a conference call and webcast to discuss the transaction on January 6, 2011. That morning, at 9:00 AM ET, Albert Eilender, Ronald Gold, and Douglas Roth will conduct a conference call. Interested parties may participate in the call by dialing 800-447-0521 (847-413-3238 for international callers) – please call in 10 minutes before the call is scheduled to begin, and ask for the Aceto call (conference ID # 28692288). The conference call will also be webcast live via the Investor Relations section of our website, www.aceto.com. To listen to the live call please go to the website at least 15 minutes early to register, download and install any necessary audio software. The slide presentation that will be discussed on the conference call and webcast will be made available on the Company's website no later than the evening of January 5, 2011. To access the slides, go to the Company's homepage and click on the link for the January 6, 2011 Rising Transaction Presentation.

The conference call will be archived on the Company's website, and a recorded phone replay will also be available from 1:00 p.m. ET on Thursday, January 6, 2011 until 5:00 p.m. ET on Monday January 10, 2011. Dial 888-843-7419 (630-652-3042 for international callers) and enter the code 28692288 for the phone replay.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New urine-based test improves identification of high-grade prostate cancer